DermatologyNews.net

Dermatology Xagena

Search results for "Melanoma"

Two clinical trials of Humira ( Adalimumab ), REVEAL and CHAMPION, have demonstrated promising results in psoriasis. Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin ...


Preliminary data from a pivotal phase 2 clinical trial of PLX4032 ( RG7204, Vemurafenib, Zelboraf ) in metastatic melanoma, showing significant tumor shrinkage in the majority of patients, are present ...


The BRAF inhibitor Vemurafenib ( Zelboraf ) represents a new standard of care for metastatic melanoma patients with BRAF V600 mutations after showing improved progression free and overall survival in ...


Researchers from UCLA's Jonsson Comprehensive Cancer Center reported that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melan ...


The results from the phase 3 trial in melanoma, which has evaluated the efficacy and safety of Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to trea ...


The European Commission has granted conditional approval to Erivedge ( Vismodegib ) for the treatment of adult patients with symptomatic metastatic basal cell carcinoma ( BCC ) or locally advanced BCC ...


Nivolumab, a human immunoglobulin G4-blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlativ ...


A phase III study of the combination of Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), compared to single agent therapy with Dabrafenib in patients with BRAF V600 E or K mutation positive unrese ...


Patients with advanced melanoma, who have been treated with the monoclonal antibody, Ipilimumab ( Yervoy ), can survive for up to ten years, according to the largest analysis of overall survival for t ...


Bristol-Myers Squibb ( BMS ) has announced that a randomized blinded comparative phase 3 study evaluating Nivolumab versus Dacarbazine ( DTIC ) in patients with previously untreated BRAF wild-type adv ...


In the BRIM-3 trial, Vemurafenib ( Zelboraf ) was associated with risk reduction versus Dacarbazine ( Deticene ) of both death and progression in patients with advanced BRAFV600 mutation-positive mela ...


Sentinel-node biopsy, a minimally invasive procedure for regional melanoma staging, was evaluated in a phase 3 trial. Researchers have evaluated outcomes in 2001 patients with primary cutaneous melan ...


OBSERVE-5 was a 5-year FDA-mandated surveillance registry of patients with psoriasis. Researchers have assessed long-term Etanercept ( Enbrel ) safety and effectiveness. Patients with moderate to s ...


Keytruda ( Pembrolizumab ) is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with ...


The results of a phase I study in advanced melanoma suggested complementary clinical activity with Nivolumab ( Opdivo ), a PD-1 checkpoint inhibitor, plus Ipilimumab ( Yervoy ), a CTLA-4 checkpoint in ...